arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

INSMED Inc

INSM
$108.72 ▼ -1.24 (-1.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

INSMED Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $21.6B
Dividend Yield —
Revenue Growth 66.7% ↗
Op. Margin -205.6% ↗
ROIC -97.4% ↘
FCF / Share $-4.86 ↘
Trailing P/E —
Price / Book 31.5x
FCF Yield —
Debt / Equity 0.74
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$606.42M
↑ +66.7% —
Net Income Profit after all expenses
$-1.28B
↓ -39.7% —
Operating Margin Operating profit as % of sales
-205.6%
↑ +14.9% 0th
FCF / Share Free cash flow per share
$-4.86
↓ -13.0% —
Long-Term Debt Long-term obligations
$546.77M
↓ -51.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Returns ↓
4
Financial Health ↓
32
Cash Quality ↓
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 67 quarters